Pfizer Japan Spinout RaQualia Cuts Another Deal With Korea's CJ CheilJedang
This article was originally published in PharmAsia News
Executive Summary
SEOUL - In a follow-up to a memorandum of understanding signed in 2010, CJ CheilJedang Corp. signed an agreement with RaQualia Pharm Inc. for exclusive rights to develop, manufacture and commercialize RaQualia's 5-HT4 partial agonist (RQ-0010) in South Korea, China, Taiwan, India and Southeast Asia
You may also be interested in...
Pfizer Japan Spin-out RaQualia Looks To Find Its Niche
Although RaQualia narrowly avoided the brunt of recent economic crises, timing still matters when finding a licensor, CEO says.
Market Snapshot: Taking Constipation Seriously – Linaclotide Success Raises Hopes For Market Resurgence
The constipation and irritable bowel syndrome markets have sucked up some prescription drug contenders like quicksand. But the Phase III success of Ironwood Pharmaceuticals' linaclotide is renewing hope that an underserved and arguably under-appreciated market could blossom, despite regulatory and commercial challenges that have hindered candidates in the past.
Korea's CJ CheilJedang and Japan's RaQualia Pharma Partner For Gastrointestinal Therapies
SEOUL - South Korea's CJ CheilJedang signed a memorandum of understanding and subsequently a licensing agreement with Japan's RaQualia Pharma to establish a strategic alliance for the latter's innovative gastrointestinal therapies